Absolutely.
New Zealand has other ways as well, but reference pricing is really the central way to do that. That's because what you're doing here is a very clever way to use market forces, market competition, in order to lower the price of drugs. You still respect patents. If the drug companies arrive with a new product that does not provide any therapeutic benefit compared to what already exists—